{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:20:01Z","timestamp":1793035201782,"version":"4.5.0"},"reference-count":21,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing\u2019s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six months later, all the cushingoid features had resolved, and s-calcitonin had decreased from 580 pmol\/L to 3.5 pmol\/L (normal &lt; 3). After further 6 months, s-calcitonin had normalized (1.5 pmol\/L), and radiological evaluation showed a profound tumour volume reduction. We are aware of two other cases where treatment with selpercatinib has also been successful. Thus, selpercatinib may be a promising treatment alternative in patients with ectopic Cushing\u2019s syndrome due to medullary thyroid cancer, especially when other treatment options are ineffective or not tolerated.<\/jats:p>","DOI":"10.3390\/curroncol29050282","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:10:32Z","timestamp":1652332232000},"page":"3494-3498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Successful Treatment with Selpercatinib for Ectopic Cushing\u2019s Syndrome Due to Medullary Thyroid Cancer"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0204-9492","authenticated-orcid":false,"given":"Oskar","family":"Ragnarsson","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Sahlgrenska University Hospital, SE-41302 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Piasecka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sahlgrenska University Hospital, SE-41302 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3705-194X","authenticated-orcid":false,"given":"Andreas","family":"Hallqvist","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sahlgrenska University Hospital, SE-41302 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ando.2021.12.002","article-title":"Updates on therapy for medullary thyroid cancer in 2021","volume":"83","author":"Puerto","year":"2021","journal-title":"Ann. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejso.2006.10.021","article-title":"Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients","volume":"33","author":"Pelizzo","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-16-0809","article-title":"Prognostic factors in ectopic Cushing\u2019s syndrome due to neuroendocrine tumors: A multicenter study","volume":"176","author":"Davi","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/thy.2005.15.618","article-title":"Ectopic Adrenocorticotropic Hormone-Syndrome in Medullary Carcinoma of the Thyroid: A Retrospective Analysis and Review of the Literature","volume":"15","author":"Barbosa","year":"2005","journal-title":"Thyroid"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cen.14617","article-title":"Medullary thyroid cancer with ectopic Cushing\u2019s syndrome: A multicentre case series","volume":"96","author":"Koehler","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/thy.2007.0062","article-title":"Predicting the development of Cushing\u2019s syndrome in medullary thyroid cancer: Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization","volume":"17","author":"Krishna","year":"2007","journal-title":"Thyroid"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1055\/s-2002-25185","article-title":"Cushing\u2019s syndrome caused by paraneoplastic ACTH secretion 11 years after occurence of a medullary thyroid carcinoma","volume":"127","author":"Kann","year":"2002","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JTO.0000000000000116","article-title":"Prognostic Impact of Paraneoplastic Cushing\u2019s Syndrome in Small-Cell Lung Cancer","volume":"9","author":"Shestaeva","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: Results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing\u2019s syndrome: Systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.28858","article-title":"Medical management of metastatic medullary thyroid cancer","volume":"120","author":"Maxwell","year":"2014","journal-title":"Cancer"},{"key":"ref_16","first-page":"16","article-title":"ACTH-secreting medullary thyroid cancer: A case series","volume":"2017","author":"Wijewardene","year":"2017","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1210\/jc.2014-3632","article-title":"Time to recovery of adrenal function after curative surgery for Cushing\u2019s syndrome depends on etiology","volume":"100","author":"Berr","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","first-page":"20","article-title":"Metastatic medullary thyroid carcinoma presenting as ectopic Cushing\u2019s syndrome","volume":"2021","author":"Forde","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_21","unstructured":"Agosto, S.S.V., Zhu, E., Nguyen, M., Kherani, J., Olek, E., Rothenberg, S.M., Kane, M., and Sherman, S.I. (November, January 30). Successful resolution of Cushing syndrome due to ectopic ACTH syndrome in metastatic medullary thyroid carcinoma during treatment with selpercatinib (LOXO-292), a novel highly selective RET inhibitor. Proceedings of the 89th Annual Meeting American Thyroid Association, Chicago, IL, USA."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/282\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:38Z","timestamp":1760137778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050282"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050282","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}